A Newly Diagnosed CML-CP HBV Carrier was Safely Treated with Dasatinib and Entecavir

[1]  Jian-yong Li,et al.  Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy , 2013, Supportive Care in Cancer.

[2]  M. Kudo,et al.  Characteristic Pattern of Reactivation of Hepatitis B Virus during Chemotherapy for Solid Cancers , 2012, Digestive Diseases.

[3]  H. Einsele,et al.  Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib , 2012, International journal of cancer.

[4]  Hideo Tanaka,et al.  Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients , 2012, International Journal of Hematology.

[5]  G. Cui,et al.  Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate. , 2012, Chinese medical journal.

[6]  E. Tanaka,et al.  Risk of hepatitis B reactivation in patients treated with tumor necrosis factor‐α inhibitors , 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

[7]  J. Y. Kim,et al.  Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports. , 2010, Transplantation proceedings.

[8]  G. Superti-Furga,et al.  Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily , 2009, European journal of clinical investigation.

[9]  Y. Chae,et al.  Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review , 2009, International journal of hematology.

[10]  D. Priebat,et al.  Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy , 2008, Hepatology international.

[11]  H. Tan,et al.  Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. , 2008, Singapore medical journal.

[12]  F. Prósper,et al.  Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825) , 2007, Leukemia & lymphoma.

[13]  H. Ohira,et al.  Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment , 2006, Leukemia & lymphoma.

[14]  I. Dervite,et al.  Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. , 2001, The New England journal of medicine.

[15]  M. Asaka,et al.  Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma , 2003, Annals of Hematology.